Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Ketamine-assisted therapy lifted me out of depression. But it remains costly — and controversial Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help ...

Esketamine may be an option for people with ... Like Winograd, she’d tried many antidepressants over the years. Ketamine therapy helped her depression and PTSD, but not her anxiety.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...

Like any drug, esketamine isn’t without its risks ... Still, Spravato’s expansion into a standalone therapy means that more people with treatment-resistant depression will be able to access ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...